Michael Mortensen
Chief Operating Officer bei BONESUPPORT HOLDING AB
Vermögen: 828 085 $ am 31.03.2024
Profil
Michael Wrang Mortensen is currently the Director of Development & Supply at Nanovi Radiotherapy A and the EVP of Research, Development & Operations at BONESUPPORT HOLDING AB.
He has a graduate degree from the Technical University of Denmark, a doctorate from the University of Copenhagen, and an MBA from AVT Business School A.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BONESUPPORT HOLDING AB
0,06% | 05.03.2024 | 38 835 ( 0,06% ) | 828 085 $ | 31.03.2024 |
Aktive Positionen von Michael Mortensen
| Unternehmen | Position | Beginn |
|---|---|---|
| BONESUPPORT HOLDING AB | Chief Operating Officer | 01.12.2021 |
Nanovi Radiotherapy A/S
 Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Corporate Officer/Principal | - |
Ausbildung von Michael Mortensen
| Technical University of Denmark | Graduate Degree |
| University of Copenhagen | Doctorate Degree |
| AVT Business School A/S | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BONESUPPORT HOLDING AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Health Technology |
